CIK 0001841387 · <br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 550,458 shares at $5.45 ($2,999,996)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Medical Officer sold 937 shares at $6.98 ($6,540)
- 4 Planned sale Chief Medical Officer sold 781 shares at $5.04 ($3,936)
- 4 Grant or award Chief Technology Officer acquired 5,353 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 42,826 shares (grant or award)
- 4 Grant or award Director acquired 1,070,663 shares (grant or award)
- 4 Grant or award Director acquired 111,349 shares (grant or award)
Page 2 of 11 · 202 filings